



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C12P 21/00, 21/02, 19/34 C12N 15/00, 5/00, C07H 15/12 C07H 13/00		A1	(11) International Publication Number: WO 88/ 03172 (43) International Publication Date: 5 May 1988 (05.05.88)
(21) International Application Number: PCT/US87/02845 (22) International Filing Date: 28 October 1987 (28.10.87) (31) Priority Application Number: 923,971 (32) Priority Date: 28 October 1986 (28.10.86) (33) Priority Country: US (71) Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER [US/US]; 1275 York Avenue, New York, NY 10021 (US). THE ROCKEFELLER UNIVERSITY [US/US]; 1230 York Avenue, New York, NY 10021 (US). (72) Inventors: RAVETCH, Jeffrey, V. ; 136 64th Street, New York, NY 10021 (US). UNKELESS, Jay, C. ; 742 Carroll Street, Brooklyn, NY 11215 (US).		(74) Agent: WHITE, John, P.; Cooper, Dunham, Griffin & Moran, 30 Rockefeller Plaza, New York, NY 10112 (US). (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), CH (European patent), DE (Euro- pean patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European pa- tent), NL (European patent), SE (European patent). Published With international search report.	
(54) Title: DNA EXPRESSING F _c RECEPTOR PROTEIN			
(57) Abstract <p>Substantially pure DNA expressing F_c receptor proteins is taught. Additionally, the proteins thus expressed and ap- plications employing these are set forth as well.</p>			
Application No.: 10/756,153 Attorney Docket No.: 13783-105015 References B10			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

DNA EXPRESSING F_C RECEPTOR PROTEINFIELD OF THE INVENTION

This invention relates to immunoglobulin receptors. In particular, it relates to nucleotide sequences which express the receptor molecules, the receptor molecules themselves, as well as transformed cell lines which produce the molecules. In addition, methods for producing the protein are taught. Finally, also taught are analogs to organs which are associated with immunoglobulin receptors.

BACKGROUND AND PRIOR ART

For the immune system to achieve the function of protecting the organism against foreign antigens, cooperation between the humoral and cellular pathways occurs via interaction of antibody-antigen complexes with effector cells, mediated by specific antibody receptors, known as Fc receptors. These receptor molecules act in a critical way to mediate binding of antibodies to effector cells, as well as in the regulation of antibody function.

Receptors for the Fc domain of immunoglobulin G, which is the most common class of immunoglobulin, are known to be present on B cells, some T cells, natural killer or "NK" cells, macrophages, and polymorphonuclear leukocytes. In

-2-

this regard see, e.g. Unkeless, et al., Adv. Immunol. 31: 247-270 (1981); Springer, et al., Contemp. Top. Immunobiol. 13: 1-31 (1984); Dickler, Mol. Immunol. 19: 1301-1306 (1982).

When immune complexes bind to Fc receptors on neutrophils and macrophages, this triggers cellular responses which include phagocytosis, release of activated oxygen metabolites, and mediators of inflammation such as leukotrienes and prostaglandins, as well as induction of neutral hydrolases. See, e.g. Nathan, et al., N. Eng. J. Med. 303: 622 (1980). Fc receptors have been described on lymphocytes as well: Uhen, et al., Cellular Immunol. 95: 368-379 (1985), where they are presumed to have a role in the modulation of antibody production by B cells.

Fc receptors have been described for all classes of immunoglobulin (IgA, IgD, IgE IgG, IgM), but very little is known about the molecules themselves. Perhaps the best characterized receptors are what are known as the "high avidity basophil/mast cell" IgE receptor (FcE), and mouse macrophage Fc receptor which binds IgG2b/IgG1 immune complexes (FcG2b/1R). With respect to murine specimens, studies of competitive binding of different IgG subclasses (Diamond, et al., J. Exp. Med. 150: 721-726 (1979); J. Immunol. 125: 631-633 (1980); J. Exp. Med. 153: 514-519 (1981), and differential sensitivity to proteases (Unkeless, J. Exp.

-3-

Med. 142: 1520 (1975); have demonstrated the presence of binding sites for IgG3 (FcG3R), IgG2a (FcG2aR), and IgG2b/G1 complexes (FcG2b/1R). The latter molecule has been described as an integral membrane glycoprotein of 50-60 K daltons, with four sites for N-linked glycosylation. See, in this regard, Green, et al., J. Biol. Chem. 260: 9867-9874 (1985).

Recent work has made it necessary to obtain detailed biochemical characterization of receptors. A monoclonal antibody, 2.4G2 is known which is directed against an epitope present on murine FcG receptors of both macrophages and lymphocytes. Unkeless, J. Exp. Med. 150: 580-596 (1979). While the epitope recognized is known to be present on macrophages and lymphocytes, work by, e.g. Phillips, et al., J. Immunol. 134: 2835-2838 (1985); Baum, et al., J. Exp. Med. 162: 282-296 (1985), and Teilland, et al., J. Immunol. 134: 1774-1779 (1985), shows that the isotype specificity of the lymphocyte receptor active with 2.4G2 is broader than FcG2b/1R, which does not bind IgG2a. Also, FcG2b/1R has been identified as an alloantigen related to the known M1 system described by Mark, et al., J. Immunol. 135: 2635-241 (1985), and Hibbs, et al., Immunogen. 22: 335-348 (1985), a locus on chromosome 1 which specifies products on antigen presenting cells and governs a non H-2T cell proliferative response resulting in intense stimulation

-4-

of the mixed lymphocyte reaction. Four alleles of the locus have been identified (Festenstein Transplantation Proceedings 8: 339-342 (1976), and the Ly-17 antigen, which is known to be identical to FcG2b/1R (Holmes, et al., Proc. Natl. Acad. Sci. 82: 7706-7710 (1985) is either closely linked to or determined by this locus.

Given the differences in isotype specificity between macrophage and lymphocyte receptors, as well as the functional heterogeneity thereof, isolation and characterization of cDNAs of macrophage and T cell clones was undertaken. The result of these experiments was isolation of two genes, one of which exists in two different allelic forms, which express proteins with highly homologous extracellular domains which bind IgG, but which possess different transmembrane and cytoplasmic domains. These genes will be referred to as Fc α R, Fc β R, and Fc δ ₂R hereafter.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the restriction map and sequencing strategy (a) and nucleotide sequence (b) for the gene expressing macrophage FcG α . UT = untranslated sequences, S = signal sequence, extracellular domain = E-C, transmembrane domain = TM, and cytoplasmic domain = C.

-5-

Figure 2 shows homology of FcG protein to MHC class II protein E . A single dot indicates conservative mutation, while two dots indicate identity.

Figure 3 shows the distribution of FcG α mRNA in various cell lines.

Figure 4 parallels Figure 1 in that it shows the restriction map and sequencing strategy (a), and nucleotide sequence of FcG β_1 cDNA (b).

Figure 5 depicts amino acid alignment of FcG α and FcG β_1 proteins. Overall, there is 95% homology in the extracellular portion.

Figure 6 shows Southern Blot Analysis of DNAs of inbred mice, and identifies a polymorphism linked to the FcG gene.

Figure 7 shows the distribution of β_2 transcripts in different cell lines, and provides evidence for a macrophage β_2 transcript.

Figure 8 shows the restriction map and sequencing strategy (a), and the nucleotide sequence (b) of FcG β_2 cDNA.

-6-

Figure 9 shows the expression of $\text{Fc}\gamma\text{R}_2$ in transfected mouse melanoma cells, via reconstitution of immunoglobulin binding activity.

Figure 10 is a summary of the structure of the IgG2b/G1 $\text{Fc}\gamma\text{R}$ cDNA genes obtained from macrophage and T cell lines.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Purification and Amino-Terminal Sequence of $\text{Fc}\gamma\text{R}$

$\text{Fc}\gamma$ receptor was purified from the S49.1 cell line by a slight modification of the published procedure of Mellman, et al. J. Exp. Med. 152: 1048 (1980). Cells (1×10^{10}) grown in suspension culture were lysed in 30 ml of 2% Nonidet P-40 in PBS containing 0.2 TIU aprotinin per ml and 5 mM diisopropylfluorophosphate. The 40,000 xG supernatant from the lysate was applied to a 5 ml column of Sepharose 4B coupled with 2 mg of 2.4G2 IgG per ml of resin. The column was washed first with 10 column volumes of 1% NP-40/0.2% sodium dodecyl sulfate in PBS, and then with 10 column volumes of 10 mM octyl- β -D-thioglucoiside in PBS. Protein was eluted with PBS containing 50 mM triethylamine, 10 mM octyl- β -D-thioglucoiside, pH 11.0 and rapidly adjusted to neutrality with Tris HCl. The protein was acidified with trifluoroacetic acid, applied to a Supelco C8 2 cm column

SUBSTITUTE SHEET

-7-

and eluted with a gradient of acetonitrile 0.1% trifluoroacetic acid, as described by Pan, et al., J. Chromatog. 297: 13-19 (1984).

The amino terminal 22 amino acids for the S49.1 IgG2b/γ1 receptor were determined on 200 pMoles of the above material using a Waters HPLC system and a microsequencing apparatus (Applied Biosystems model 470A) and found to be THDLPKAVVKLEPPWVQLKED. The seven amino acids EPPWVQL were chosen for the synthesis of a corresponding oligodeoxynucleotide based on their relatively low degeneracy. After considering preferred codon usage described by Chen, et al., DNA 4: 365-374 (1982) and the ability of G-T base pairing to form, a 20 nucleotide sequence was synthesized that corresponds to the complementary strand of the sequence encoded above. That sequence is 5' ACTTG^G_TATCCA^G_TGG^G_TGGTTC 3'.

Nucleotide and Deduced Protein Sequence of the Macrophage FcγRα

The low degeneracy mixed probe described supra was end-labelled to high specific activity with ³²P-γATP and used to screen a mouse macrophage cDNA library constructed to size-fractionated J774 mRNA in the plasmid vector pUC9

SUBSTITUTE SHEET

-8-

(Portnoy, et al., J. Biochem. (1986). A library of 50,000 clones was screened from which 2 positives were identified.

The screening involved a hybridization reaction which included 6X NETS, IX Denhardt's, 10^6 cpm/ml 32 P-end labelled oligonucleotide (10^9 cpm/ μ g) at 45°C for 16 hours. The filters were then washed in 6X SSC at 25° for 5 minutes, followed by a 40°C wash in the buffer described supra for 1 minute, followed by a 1 minute wash in the same buffer at 45°C . Filters were dried, autoradiographed for 6 hours at -70°C with intensifying screens and developed. Positive clones were identified and the filters rewashed at 50°C in 6X SSC for 1 minute and then at 65°C for 1 minute. Positives melt off differentially at the higher temperature and were subjected to colony purification, plasmid preparation and restriction analysis. The clone with the largest insert (a 1300 base pair PstI fragment) was chosen for subsequent analysis. The sequencing strategy for this clone is presented in Figure 1a with the nucleotide sequence and deduced amino acid sequence in Figure 1b. An open reading frame of 782 nucleotides was found, beginning with an ATG at position 64 and terminating at position 846. The predicted signal peptidase cleavage site is indicated by an arrow and is assigned based on the consensus rules for such

SUBSTITUTE SHEET

-9-

sequences (Von Heijne, Eur. J. Biochem 133: 17-21 (1983)). 19 amino acids, encoded from nucleotides 160-210, are identical to amino acids 3-22 of the S49.1 sequence presented above, with the exception of position 12 which is a glutamic acid residue in S49.1 and an aspartic acid in J774. The discrepancy in the first three amino acids and position 12 resulted from the heterogeneity between the macrophage and T cell proteins, described infra. A 30 amino acid signal sequence is predicted, and is numbered -30 to -1 with a hydrophobic core overlined. Predicted signal peptidase cleavage site is indicated by the arrow between -1 and 1 following Von Heijne, supra. N-linked glycosylation sites are boxed and cysteine residues circled. The deduced protein sequence contains two regions of hydrophobic amino acid residues, overlined in Figure 1b. These regions encode the putative signal sequence (nucleotides 64-153) and a transmembrane anchor sequence (nucleotides 709-769). An extracellular domain of 185 amino acids is expected for the mature protein which contains 4 potential N-linked glycosylation sites (boxed in Figure 1b) as well as four cysteine residues which could form 2 intra-chain disulfide bonds. A serine and threonine rich region is encoded from amino acids 155-185, just preceding the transmembrane

-10-

domain, in which 30% of the residues are represented by these two amino acids. A cytoplasmic domain of 26 amino acids is predicted from this sequence. The primary sequence predicts a molecular weight of 30,040 daltons, which would then be subject to glycosylation at the four N-linked sites described, and possibly O-linked sites as well.

The extracellular domain described above consists of two internally repeated sequences. Amino acids 25-75 of the predicted mature protein show homology to amino acids 100-155. These homologies cluster around the cysteine residues, suggesting a structural repeating domain. These data suggest that the extracellular domain consists of a repeated domain defined by the cysteine residues. Comparison of this sequence to the protein sequence databanks revealed significant homology to immunoglobulin molecules, MHC class I and class II proteins, $\delta 2$ microglobulin and other members of this supergene family. Homology of the extracellular domain with a rabbit V region has been demonstrated showing clusters of homology centered about the cysteine residues in both proteins. This homology suggests that this Fc receptor contains two immunoglobulin-like domains, each consisting of a potential disulfide loop of 42 amino acids within a domain of 70-80 amino acids.

-11-

The most significant homology we found for this FcR is to the MHC class II protein E β , with 32% identity over a 91 amino acid region, as shown in Figure 2a. Random shuffling of these two sequences, using the program rdf (Lipman, et al., Science 227: 1435-1441 (1985), indicated that the optimized alignment shown in Figure 2a is highly significant, at 5 standard deviations above the mean. This homology to E β occurs in the β_2 domain (Figure 2b) which itself is an immunoglobulin-like domain. Homology is also apparent by this analysis in the transmembrane domain of these two proteins.

mRNA extracted from a variety of cell lines was analyzed for the presence of message corresponding to the cDNA cloned from the J774 cell line, referred to as the α gene. The procedure used generally followed Chitgwin, et al., Biochem. 18: 5294 (1979), and Lehrach, et al., Biochem. 16: 4743-4751 (1977). Briefly, 1 μ g of poly A⁺ RNA was fractionated on agarose-formaldehyde gels transferred to nitrocellulose and hybridized under stringent conditions either with the complete α probe (a) or a probe constructed to the 5' α sequences (b). As can be seen in Figure 3, a broad band of hybridization is detected in the macrophage lines P 388D1, WEHI, 3A, RAW 264.7 and J774. A T cell line

-12-

S49.1, which reacts with the FcγR monoclonal antibody 2.4G2 contains a higher molecular weight mRNA species. P388 demonstrates two RNA species of equivalent abundance, while WEHI 3A has a major band migrating faster than 18S and a band of much lower abundance migrating slower than 18S. 2.4G2 negative lines CL.7 (fibroblast), L-cell (fibroblast) and L51789 (T cell) do not contain an α transcript. The cell type specificity of expression of the α gene was apparent when a probe was constructed to the 5' sequences of the cDNA and used to examine the same macrophage and T-cell RNAs (Figure 3b). No transcript is detected in the S49.1 cell line with this probe and only a single species is seen in P388. Similarly, the lower abundance species migrating slower than 18S in WEHI 3A is not detected with this probe. Similar results were obtained when a 3' probe was constructed from the α cDNA (Sca-Pst, data not shown). These results show that the T cell line S49.1 and the macrophage-like lines P388 and WEHI 3A contained cross-hybridizing RNA species when probed with the complete probe which are not homologous to the macrophage α transcript on their 5' and 3' ends. Analysis of two other T cell lines EL-4 and K-36 demonstrated transcripts of similar size to that found in S49.1 (data not shown). To identify

SUBSTITUTE SHEET

-13-

these transcripts and the genetic basis for their expression, a cDNA library was constructed to size-fractionated S49.1 mRNA and probed with the complete cDNA α probe. Positive clones were identified at a frequency of .1% and were characterized by restriction mapping and DNA sequence analysis.

Figure 4a presents the physical map and sequencing strategy for the T cell transcript, referred to as β_1 , and 4b presents the nucleotide sequence and predicted amino acid sequence for this protein. The procedures used were the same as those described supra for obtaining the physical map and sequence of macrophage DNA. A single open reading frame was found, beginning with an ATG at nucleotide 340 and terminating at nucleotide 1326. The predicted molecular weight of this protein before modification is 36,750 daltons. Beginning at nucleotide 427 (position +1) 22 amino acids are encoded which are identical to the determined amino terminal sequence for this protein. The sequence which precedes this N terminus encodes a signal sequence with a characteristic hydrophobic core (overlined), which bears no homology to the signal sequence of the α transcript (see Figure 1b). The extracellular domain has 95% identity with the α sequence, as shown in Figure 5, beginning at

-14-

amino acid 4 of the β_1 sequence and continuing through amino acid 174. A transmembrane and cytoplasmic domain are predicted for the β_1 sequence, which bear no homology to the analogous domains of the sequence. No sequence homology is found in the 5' and 3' untranslated domains of these two transcripts.

Four additional tryptic peptides were sequenced for the S49.1 Fc γ R. A 10 amino acid sequence SQVQASYTFK was confirmed at positions 50-59 of the β_1 sequence; the 8 amino acid sequence ISFFHNEK was confirmed at positions 120-127; the 13 amino acid sequence EMGETLPPEEVGEY was present at positions 222-235, and finally the 13 amino acid sequence TEAENTITYSLK was confirmed at positions 271-283.

Since both α and β_1 sequences were obtained from cell lines derived from Balb/c mice, the 5% sequence variation in the highly conserved extracellular domain could not arise from allelic variation. To confirm that the β_1 transcript was derived from a second gene, Southern blot analysis of DNA obtained from different inbred strains of mice was used to map the α and β genomic sequences. As seen in Figure 6, DNA cut with Taq I and probed with the complete α probe detects a polymorphism associated with this gene, giving rise to three different restriction fragment lengths. This

SUBSTITUTE SHEET

-15-

polymorphism resides 3' of the α gene, as determined by reprobing these blots with 5' and 3' probes (data not shown). However, when these same DNA samples are probed with the complete β_1 cDNA probe (Figure 6b), the 3' polymorphic fragment associated with the α gene is replaced by 2.4 kb non-polymorphic fragment. These data suggest that the α and β transcripts are derived from different genes, which contain a highly conserved sequence encoding an extracellular domain. Hybridization with both the α and β probes under conditions of low stringency (25% formamide, 10% dextran sulphate, 5X SSC at 40°C; final wash = .2X SSC, .1% SDS 40°C) revealed an additional cross-hybridizing restriction fragment, perhaps suggestive of a third member of this gene family (not shown).

Expression of the β Gene in T cell and Macrophage Lines

Figure 7a presents the result of RNA blot analysis of macrophage and T cell lines probed with the β_1 cDNA probe. This probe is expected to detect the S49.1 transcript, as well as cross-hybridize to the α transcript in macrophage lines. However, comparing the results of this blot with that in Figure 4a it is clear that a different pattern of transcripts are detected with different abundance. In

SUBSTITUTE SHEET

-16-

particular WEHI 3A and P388 demonstrates two transcripts of comparable abundance one of which has the same apparent mobility as the S49.1 transcript. This is confirmed by using a 5' β_1 probe, shown in Figure 7b, constructed to the 5' untranslated region of this transcript in which no homology to the α gene is found. Transcripts are detected in macrophage lines with this probe, demonstrating that the β gene is expressed in macrophages, resulting in a different transcript size in J774, RAW and P388D1 than what is found in the S49.1 T cell line. To investigate these macrophage β transcripts, the J774 cDNA library was screened with both unique and common sequences derived from the β gene. Restriction enzyme mapping of the clones obtained demonstrated that these clones differed from the β_1 transcript of the S49.1 cell line in lacking an Xmn site. The physical map and sequencing strategy for the macrophage β transcript, referred to as β_2 is shown in Figure 8a and the nucleotide sequence and deduced amino acid sequence in Figure 8b. The procedure followed for obtaining these was the same as that given supra.

-17-

Comparison of the β_1 and β_2 Transcripts: Evidence for a T Cell Specific Splice in the Cytoplasmic Domain

The β_1 and β_2 sequences are identical throughout their length, both for coding and noncoding sequences, with the exception of a 138 nucleotide insertion found in the β_1 sequence (nucleotides 1066-1204, indicated by the upward arrows in Figure 4b) which occurs after nucleotide 783 in the β_2 sequence. This sequence results in a 46 amino acid insertion in the cytoplasmic domain of the β_1 transcript. This insertion accounts for the larger transcript found in S49.1 as well as in the T cell lines EL-4 and K-36 (data not shown). RNase protection using a T7 RNA polymerase generated radiolabelled RNA probe specific for the β_1 gene (Xmn-Pst, see Figure 4a) detected a 500 nucleotide protected fragment, specific for the β_1 gene, in the S49.1 and K-36 T cell lines and not in the macrophage line P388D1. In addition to the 500 bp protected fragment, a 362 bp fragment was detected in S49.1 and K-36 which comigrated with the P388D1 macrophage protected fragment, consistent with the size expected to be protected by the β_2 transcript. These results suggest that the β gene is transcribed in T cells and macrophages. In T cells, however, a transcript with a 138 bp insertion is found, which is most simply explained by

-18-

an alternative splicing pathway which gives rise to an additional exon in the T cell FcγR β . The predicted molecular weight of the β_2 protein is 31,886 prior to any post-translational modification.

Functional Domains of the FcγR: Expression in Transfected Cell Lines

In order to begin to assess the functional role of the structural heterogeneity described for this Fc receptor and to ascertain if more than one polypeptide chain was necessary for ligand binding, Fc receptor negative cell lines were transfected with these cDNA clones. Expression was achieved by cloning the coding sequence of the β_1 or β_2 cDNAs into an expression vector (pcEXV-3) as described by Miller, et al., J. Immunol. 134: 4212-4217 (1985) which utilizes the SV40 early promoter to achieve transcription of the cloned sequences. B78H1 mouse melanoma cells were cotransfected with the plasmid constructions and pGCCos3neo, which confers resistance to the drug G418 (Southern, et al., J. Mol. Appl. Genet. 1: 327-341 (1982)). After 10 days in G418 containing medium colonies were screened by rosetting with human erythrocytes conjugated with the monoclonal

-19-

antibody 2.4G2, as described by Albino, et al., Mol. & Cell Biol. 5: 692-697 (1985). Positive cells were cloned and then tested for Fc γ receptor activity.

Figure 9 presents the results obtained with the β_2 cDNA cloned into the expression vector. Stable lines expressing the 2.4G2 epitope avidly bound sheep red blood cells opsonized with rabbit anti-SRBC, which is diagnostic of Fc γ receptor function. In addition, this binding is blocked in a concentration dependent fashion by the monoclonal antibody 2.4G2, demonstrating the specificity of binding to this receptor. Transfectants which were obtained with the β_1 insert in the expression vector demonstrated the same pattern of binding. Controls with untransfected B78H1 cells, transfected cells in which the Fc γ R β sequences were in the reverse orientation with respect to the SV40 promoter as well as studies with SRBCs not coated with antibody all gave negative results (data not shown). These experiments indicate that the protein expressed by these cDNA clones is able to be displayed on the cell surface and mediate the binding of antibody-antigen complexes in a specific manner. Experiments with other cell lines, such as mouse L cells or monkey cos cells suggests that the ability of these sequences to specify an Fc receptor is not cell type specific.

-20-

Two genes have been identified that encode Fc γ receptors. One of these, referred to as α , is expressed in macrophage cell lines and peritoneal macrophages. The second gene, referred to as β , is expressed in both macrophage and in T-cell lines. These genes encode transmembrane proteins with two repeated N-terminal domains each containing two glycosylation sites, and a potential intrachain disulfide loop of 42-45 amino acids. This predicted structure is consistent with in vivo labeling studies, which have suggested the presence of 4 N-linked glycosylation sites. While the extracellular domains of the γ and β genes are 95% homologous, the transmembrane and cytoplasmic domains encoded by the two genes are totally different, which suggests that the different functions of lymphocyte and macrophage Fc γ receptors derives in part from different signaling mechanisms.

There is, however, still another level of complexity in this gene system, since there appear to be cell-specific splicing mechanisms that may result in altered protein products. Although the β gene is transcribed in both T cell lines and in macrophages, analysis of the T cell specific transcript (β_1) revealed an additional 138 nucleotides, which result in a 46 amino acid insertion in

SUBSTITUTE SHEET

-21-

the cytoplasmic domain of the T cell lines Fcγ receptor. RNase protection experiments have shown that the β_1 transcript is seen in T cell lines, and not in the J774, P388D1 or RAW macrophage cell lines and most probably arises from an alternative splicing pathways for the β gene. The early macrophage lines P388 and WEHI 3A have β transcripts of the same apparent mobility as the T cell lines which may suggest that β_1 splicing is developmentally regulated during macrophage maturation. The consequences of the insertion are not understood, but it is possible that the longer cytoplasmic domain in the β_1 FcγR interacts differently with cytoplasmic or membrane proteins involved in signal transduction. The structures of the three transcripts derived from the α and β genes are summarized in Fig. 10.

The sequences obtained for these receptors demonstrate that the Fcγ receptor belongs to the immunoglobulin supergene family, as does the poly IgA receptor, which functions in the transport of IgA across epithelial cells (Mostov, et al., Nature 308: 37-43 (1984)). Apart from the overall immunoglobulin homology, several other significant homologies were identified for the FcγR. The extracellular domain of the α and β genes are most homologous to the MHC class II protein E β in its β_2 domain. The poly Ig

SUBSTITUTE SHEET

-22-

receptor, by contrast, has little significant homology to the Fc γ receptor described here, suggesting that it is more distantly related to the Fc γ receptor than are class II determinants. The other significant homology detected for the transmembrane domain of the α chain, but not the β chain, is with one of the transmembrane domains of the chain of the acetylcholine receptor. Young et al., Proc. Natl. Acad. Sci. 80: 1636-1640 (1983) and Nelson, et al., J. Clin. Invest 76: 500-507 (1985) have reported ion channel activity in response to binding of ligand to Fc γ receptors. The precise role of the various structural domains of these Fc receptor proteins is under investigation.

Applications of the foregoing aspects of the invention will be recognized by one skilled in the art. For example, in some individuals with immune disorders, the cause can be traced to cells and organs which do not express the necessary Fc receptor proteins, and therefore do not mount a sufficient or complete response to infections. Artificial organs are contemplated, which either incorporate therein Fc receptor proteins produced in vitro by appropriate transformed cells in culture, or organs which are "seeded", with physiologically acceptable transformed cells which also produce the necessary protein.

SUBSTITUTE SHEET

-23-

A second application will be seen in the use of DNA of this invention to obtain human DNA corresponding to the DNA described herein. One may now follow established techniques of DNA hybridization, e.g., to locate and hybridize human Fc receptor protein expressing DNA with murine "probes". The details of such hybridization technologies are known to those skilled in the art and need not be elaborated upon further.

While there have been described what are at present considered to be the preferred embodiments of this invention, it will be obvious to one skilled in the art that various changes and modifications may be made therein without departing from the invention, and it is, therefore, aimed to cover all such changes and modifications as fall within the true spirit and scope of the invention.

-24-

WHAT IS CLAIMED IS:

1. Substantially pure nucleotide sequence expressing Fc receptor protein.
2. Nucleotide sequence of claim 1, wherein said receptor protein is Fc γ receptor protein.
3. Nucleotide sequence of claim 2, wherein said receptor protein is Fc γ^a receptor protein.
4. Nucleotide sequence of claim 2, wherein said receptor protein is Fc γ_b receptor protein.
5. Nucleotide sequence of claim 4, wherein said Fc γ_b receptor protein is Fc γ_b receptor protein.
6. Nucleotide sequence of claim 4, wherein said Fc receptor protein is Fc γ_b ₂ receptor protein.

SUBSTITUTE SHEET

-25-

7. Nucleotide sequence of claim 3, comprising sequence:

-30

GTAGTTCACTCTCTGAACCTCATCAGACTCTGATCCAGTTCTTGAATGACTTTGGACACCCAGATGTTTTCAAAAT
10 20 30 40 50 60 70

GCACACTCTTGAAGCCAATGGCTACTTCCACCACGACAATTCGCTGCTGTTTGCTTTTGCAGACAGGCAGAGT
85 95 105 115 125 135 145

-1 | 1 10

GCAGCTCTTCGAAGGCTGTGGTGAACCTGGACCCCCCATGGATCCAGGTGCTCAAGGAAGACATGGTGACACTG
160 170 180 190 200 210 220

30 40

ATGTGCGAAGGGACCCACAACCCCTGGGAACCTCTTCTACCCAGTGGTTCCACAACGGGAGGTCCATCCGGAGCCAG
235 245 255 265 275 285 295

50 60 70

GTCCAAGCCAGTTACACGTTTAAGGCCACAGTCAATGACAGTGAGAAATATCGGTGTCAAA TGGAGCAGACCCGC
310 320 330 340 350 360 370

80 90

CTCAGCGACCCCTGTAGATCTGGGAGTGATTTCTGACTGGCTGCTGCTCAGACCCCTCAGCGGGTGTTCGGAA
385 395 405 415 425 435 445

100 110 120

GGGGAACCA TCAGCTAAGGTGCCATAGCTGGAGGAACAACTACTGAACAGGATCTCATTCTCCATAA TGA
460 470 480 490 500 510 520

130 140

AAATCCGTGAGGTATCATCACTACAAAAGTAATTTCTCTATCCAAAAGCCAACCACAGTCACAGTGGGACTAC
535 545 555 565 575 585 595

150 160 170

TACTGCAAAGGAAGTCTAGGAAGTACACAGCACCAGTCCAAGCCTGTCACCATCACTGTCCAAGATCCAGCAACT
610 620 630 640 650 660 670

180 190

ACATCCTCATCTCTCTAGTCTGGTACCACACTGCTTTCTCCTAGTGA TGTGCCTCCTGTTTGCAGTGGACAG
685 695 705 715 725 735 745

200 210 220

GGCCTTTATTTCTACGTACGGAGAAA TCTTCAAACCCCGAGGGAGTACTGGAGGAAGTCCCTGTCAATCAGAAAG
760 770 780 790 800 810 820

-26-

230

CACCAGGCTCCTCAAGACAAGTGACACCCCATCCATCCTATGGCAAAACATACGATGTTTTGGTGGCAGCAGCAA
835 845 855 865 875 885 895

CTTTTCAGCCACACAGCCTTCCTTTGAAAGCAACTTACAAGCAGGCCGGGATGTTTGGTTCTTCAATCACAACGA
910 920 930 940 950 960 970

CTTAGGATCACCAGTTCAAGGCTTGCTGGGTCACACAGAGAGAGTGAGTGCAAGTCTAGCCTGGATAACCCAGTG
985 995 1005 1015 1025 1035 1045

AGATCCTGGGTTTAGGCGGCTCATCAGGAAAGAGAACCTGTTGCTAATCTCACAACAAGATGCCTACTGCCCAT
1060 1070 1080 1090 1100 1110 1120

GTGGCCAAAGGAGAGAACAAGGTCCTGGAAGTTGCTCTGACCTCCACCATCCACCATGGCAGGTGCACACAAT
1135 1145 1155 1165 1175 1185 1195

AAATTAAATGTCATGTATATTTTTAAACAAGAGACAGGGGCAGGCTAAGGGTTGATGGCATAGCTGTTATCCAG
1210 1220 1230 1240 1250 1260 1270

TACACATAATGCCCTGGGTTTGACCTCCTATAATAAAGCAAAAAAAAAAAAAAAAAAAAAA
1285 1295 1305 1315 1325 1335

SUBSTITUTE SHEET

-27-

8. Nucleotide sequence of claim 5, comprising sequence:

AATGTATGTCAGGATGAGTGTCTACTGCTGTTCTCACATATGGCCTAGCTTTTGGTCTACAATCCAACAGTGA
10 20 30 40 50 60 70

GCTGGGGATTGTGATAATAGAGAAACCCAGATGGTGACTGAGGCAAAATGACTTCTGAGCTGCGTTGGGGTGAAGT
85 95 105 115 125 135 145

TTTCCTCTCTGTACCAGACGTCCAGGTCAGCTACGGCTCCAGCAGAACATGAAGGGAGTTGTTCTCAGTGTCT
160 170 180 190 200 210 220

AAAAAATTTTCTGTGATTGAGCTGAATCCAGTTTATTCTGCGGGAGGAAGCCTGTGCGTGCAGCTGACTCGCT
235 245 255 265 275 285 295

CCAGAGCTGATGGGAATCCTGCGCTTCTACTGATCCCCATGGAGAGCAACTGGACTGTCCATGTGTTCTCACGG
310 320 330 340 350 360 370

-1 1

ACTTTGTGCCATATGCTACTGTGGACAGCCGTGCTAAATCTTGCTGCTGGGACTCATGATCTTCCAAAGGCTGTG
385 395 405 415 425 435 445

10 20 30

GTCAAACCTCGAGCCCGCTGGATCCAGGTGCTCAAGGAAGACACGGTGACACTGACATCGGAAGGGACCCACAAC
460 470 480 490 500 510 520

40 50

CCTGGAACTCTTCTACCCAGTGGTTCCACAAATGGGAGGTCCATCCGGAGCCAGGTCCAAGCCAGCTACACGTTT
535 545 555 565 575 585 595

60 70 80

AAGGCCACAGTCAATGACAGTGGAGAATATCGGTGTTAAATGGAGGAGACCCGCTCAGCGACCCCTGTAGATCTG
610 620 630 640 650 660 670

90 100

GGAGTGATTTCTGACTGGCTGCTGCTCCAGACCCCTCAGCTGGTGTCTTCTGGAAGGGGAAACCATCACGCTAAGG
685 695 705 715 725 735 745

120 130

TGCCATAGCTGGAGGAACAACTACTGAACAGGATCTCGTTCTTCCATAATGAAAAATCCGCTGAGGTATCATCAC
760 770 780 790 800 810 820

140 150

TACAGTAGTAAATTTCTCTATCCAAAAGCCAAACACAGTCACAGTGGGGACTACTACTGCAAAGGAAGTCTAGGA
835 845 855 865 875 885 895

160 170 180

AGGACACTGCACCAGTCCAAGCCTGTCAACATCACTGTGAAAGGGCCCAAGTCAGCAGGTCTTATCAGTATG
910 920 930 940 950 960 970

190 200

ACAATTGTGGCTGCTGCTCACTGGGATTGCTGTCGACGCCATTGTTATTATGCTATCCTTGGTCTATCTCAAG
985 995 1005 1015 1025 1035 1045

-28-

210 220 230
AAAAAGCAGGTTCCAGCTCTCCAGGAAACCTGATCACAGGGAATGGGAGAAACCTTCAGAGGAAGTAGGT
1060 1070 1080 1090 1100 1110 1120
240 250
GAGTACAGACAACCTCTGGGCTCAGTGCCTGTCAGCCCAGGGCTCCATCTGGACTGGAGCCAACAAGCAGCAGC
1135 1145 1155 1165 1175 1185 1195
260 270 280
CCATACAATCTCTGATCTGGAAGAAGCTGCCAAAACAGGCTGAGAATACGATCACCTACTCACTTCTCAAG
1210 1220 1230 1240 1250 1260 1270
290 300
CATCCCGAAGCCCTGGATGAAGAAACAGAGCATGATTACCAGAACCACATTTAGTCTCCCTGGCATTGGGAAAA
1285 1295 1305 1315 1325 1335 1345
GCAAGCCAGAAAGGCCAGGATCTAGTGTCTCTGGTCCAAGGATGCTGTAGATATTAAAGAAAACATCCAGAGT
1360 1370 1380 1390 1400 1410 1420
CACTTCTGTGAGTCTGAAACCAACAGACACTACGAGATTGTTCCCAATGGTTGACTGTACTAATGACTCCCAT
1435 1445 1455 1465 1475 1485 1495
AACTTACAGCTTCCCAACTCAAGACTCTTCTGCTATCGATCCACACTGCCACTAAAATTAATCAACTTACTGCC
1510 1520 1530 1540 1550 1560 1570

SUBSTITUTE SHEET

-29-

9. Nucleotide sequence of claim 6, comprising sequence:

-29

CTTGCAGCTGACTCGCTCCAGAGCTGATGGGAATCCTGCCGTTCTACTGATCCCCATGGAGAGCAACTGGACTG
10 20 30 40 50 60 70

-10 -111

TCCATGTGTTCTCAGGAACTTTGTGCCATATGCTACTGTGGACAGCCGTGCTAAATCTTGCTGCTGGGACTCATG
85 95 105 115 125 135 145

10 20

ATCTTCCAAAGGCTGTGGTCAAACCTCGAGCCCCCGTGGATCCAGGTGCTCAAGGAAGACACGGTGACACTGACAT
160 170 180 190 200 210 220

30 40 50

GCGAAGGGACCCACAACCCCTGGGAACTCTTCTACCCAGTGGTTCCACAA TGGGAGGTCCATCCGGAGCCAGGTCC
235 245 255 265 275 285 295

60 70

AAGCCAGCTACACGTTTAAGGCCACAGTCAATGACAGTGGAGAATATCGGTGTCAAATGGAGCAGACCCGCTCA
310 320 330 340 350 360 370

80 90 100

GCGACCCCTGTAGATCTGGGAGTGATTCTGACTGGCTGCTGCCAGACCCCTCAGCTGGTGTCTTCTGGAAGGGG
385 395 405 415 425 435 445

110 120

AAACCATCACGCTAAGGTGCCATAGCTGGAGGAACAACTACTGAACAGGATCTCGTTCTTCCATAATGAAAAAT
460 470 480 490 500 510 520

130 140 150

CCGTGAGGTATCATCACTACAGTAGTAATTTCTCTATCCCCAAAGCCAACCACAGTCACAGTGGGGACTACTACT
535 545 555 565 575 585 595

160 170

GCAAAGGAAGTCTAGGAAGGACACTGCACCAGTCCAAGCCTGTCACCATCACTGTCCAAGGGCCCAAGTCCAGCA
610 620 630 640 650 660 670

180 190 200

GGTCTTTACCAGTATTGACAATTGTGGCTGCTGCTCACTGGGATTGCTGTGCGAGCCATTGTTATTATCCTAGTAT
685 695 705 715 725 735 745

SUBSTITUTE SHEET

-30-

210 220
CCTTGGTCTATCTCAAGAAAAAGCAGGTTCCAGACAATCCTCCTGATCTGGAAGAAGCTGCCAAAAGTGGGCTG
760 770 780 790 800 810 820
230 240 250
AGAATACGATCACCTACTCACTTCTCAAGCATCCCGAAGCCCTGGATGAAGAAACAGAGCATGATTACCAGAACC
835 845 855 865 875 885 895
254
I
ACATTTAGTCTCCCTTGGCATTGGGAAAAGCAAGCCAGAAAGGCCAGGATCTAGTGTCTCCTGGTCCAAGGGATG
910 920 930 940 950 960 970
CTGTAGATATTAAAGAAAACATCCAGAGTCACTTCTGTGAGTCCTGAAACCAACAGACACTACGAGATTGGTTCC
985 995 1005 1015 1025 1035 1045
CAATGGTTGACTGTACTAATGACTCCATAACTTACAGCTTCCCACTCAAGACTCTTCTGCTATCGATCCACAC
1060 1070 1080 1090 1100 1110 1120
TGCCACTAAAATTAATCAACTTACTGCCGTTAAGAGA
1135 1145 1155

SUBSTITUTE SHEET

-31-

10. Substantially pure Fc γ receptor protein.
11. Substantially pure Fc γ receptor protein of claim 10, wherein said protein is Fc γ α protein.
12. Substantially pure Fc γ receptor proteins of claim 10, wherein said protein is Fc γ β protein.
13. Substantially pure Fc γ β receptor protein of claim 12, wherein said protein is Fc γ β ₁ protein.
14. Substantially pure Fc γ β receptor protein of claim 12, wherein said protein is Fc γ β ₂.

SUBSTITUTE SHEET

-32-

15. Substantially pure protein of claim 11, comprising amino acid sequence:

M P O N

A H S G S Q W L L P P L T I L L L P A F A D R Q S
A A L P K A V V K L D P P W I Q V L K E D M V T L
M (C) E G T H N P G (N S S) T Q W F H N G R S I R S Q
V Q A S Y T F K A T V (N D S) G E Y R (C) Q M E Q T R
L S D P V D L G V I S D W L L L Q T P Q R V P L E
G E T I T L R (C) H S W R N K L L N R I S P F P H N E
K S V R Y E H Y K S (N F S) I P K A (N H S) H S G D Y
Y (C) K G S L G S T Q H Q S K P V T I T V Q D P A T
T S S I S L V W Y H T A P S L V H C L L P A V D T
G L Y F Y V R R N L Q T P R E Y W R K S L S I R K
R Q A P Q D K

SUBSTITUTE SHEET

-33-

16. Substantially pure protein of claim 13, comprising amino acid sequence

M E S N W T V H V F S R
T L C H M L L W T A V L N L A A G T H D L P R A V
V R L E P P W I Q V L K E D T V T L T © E G T H N
P G N S S T Q W F H N G R S I R S Q V Q A S Y T F
K A T V N D S G E Y R © Q M E Q T R L S D P V D L
G V I S D W L L L Q T P Q L V F L E G E T I T L R
© H S W R N K L L N R I S F P H N E R S V R Y H H
Y S S N F S I P K A N H S H S G D Y Y © K G S L G
R T L H Q S K P V T I T V Q G P K S S R S L P V L
T I V A A V T G I A V A A I V I I L V S L V Y L R
K R Q V P A L P G N P D H R E N G E T L P E E V G
E Y R Q P S G L S A C Q P R A P S G L E P T S S S
P Y N P P D L E E A A R T E A E N T I T Y S L L R
H P E A L D E E T E H D Y Q N H I

SUBSTITUTE SHEET

-34-

17. Substantially pure protein of claim 14, comprising amino acid sequence:

M E S N W T V

H V F S R T L C H M L L W T A V L N L A A G T H D
-1↓1
L P K A V V K L E P P W I Q V L K E D T V T L T ©
E G T H N P G N S S T Q W F H N G R S I R S Q V Q
A S Y T F K A T V N D S G E Y R © Q M E Q T R L S
D P V D L G V I S D W L L L Q T P Q L V F L E G E
T I T L R © H S W R N K L L N R I S P F E N E K S
V R Y H H Y S S N F S I P K A N H S E S G D Y Y ©
K G S L G R T L H Q S K P V T I T V Q G P E S S R
S L P V L T I V A A V T G I A V A A I V I I L V S
L V Y L K K K Q V P D N P P D L E E A A K T E A E
N T I T Y S L L K H P E A L D E E T E E D Y Q N E

SUBSTITUTE SHEET

-35-

18. A method of obtaining substantially pure Fc receptor protein comprising transforming a eukaryotic cell with substantially pure nucleotide sequence expressing an Fc receptor protein selected from the group consisting of Fc α , Fc β_1 and Fc β_2 receptor protein culturing said transformed cell under conditions favoring expression purifying of said protein, and said expressed protein.
19. Vector which expresses Fc receptor protein, comprising a substantially pure nucleotide sequence expressing Fc receptor protein selected from the group consisting of Fc, Fc β , and Fc β_2 ligated into a portion of carrier DNA.
20. Vector of claim 19, wherein said vector is pcEXV-3.
21. Eukaryotic cell line transformed with a foreign nucleotide sequence which expresses an Fc receptor protein selected from the group consisting of Fc α , Fc β , and Fc β_2 .
22. An immunoglobulin receptor organ analog which comprises a physiologically acceptable cell line of claim 21.

SUBSTITUTE SHEET

-36-

23. A method for obtaining substantially pure human DNA which expresses human Fc receptor proteins comprising contacting a sample containing said substantially pure human DNA with a sample of mouse DNA which expresses mouse Fc receptor protein under conditions favoring hybridization between said mouse DNA and complementary human DNA, treating said sample to separate hybridized DNA from unhybridized DNA and removing said mouse DNA from said hybrid.


24. Method of claim 23, wherein said DNA expresses a receptor protein selected from the group consisting of Fc γ , Fc γ α , Fc γ β ₁, and Fc γ β ₂.

25. Substantially pure human DNA obtained by the method of claim 23.

SUBSTITUTE SHEET

1/23


FIGURE 1a

 $\gamma_{2b}/\gamma_1 F_c R \alpha$ (J774)

SUBSTITUTE SHEET

2/23

Figure 1b



SUBSTITUTE SHEET

3/23

Figure 1b, cont.

```

100      110      120
G E T I T L R C B S W R N K L L N R I S P P H N E
GGGAAACCATCAGCGTACCATAGCTGGAGGAACAACACTACTGAACAGGATCTCATTTCTTCATAATGAA
460      470      480      490      500      510      520

130      140
K S V R Y B H Y K S N P S I P K A N H S B S G D Y
AAATCCGTGAGGTATCATCTACTACAAAGTAATTTCTCTATCCCAAGCCACACAGTCACAGTGGGGACTAC
535      545      555      565      575      585      595

150      160      170
Y C K G S L G S T Q H Q S K P V T I T V Q D P A T
TACTGCAAGGAAGTCTAGGAAGTACACAGCACCCAGTCCAGCCCTGTCACCATCATCTGTCCAAGATCCAGCAACT
610      620      630      640      650      660      670

180      190
T S S I S L V W Y H T A P S L V H C L L P A V D T
ACATCCTCATCTCTAGTCTGGTACCACACTGCTTCTCCCTAGTCAATGTGCTCCTCTGTTTGCAGTGGACAG
685      695      705      715      725      735      745

200      210      220
G L Y P Y V R R N L Q T P R E Y W R K S L S I R K
GGCCTTTATTTCTACGTACGGAGAAATCTTCAAAACCCCGAGGGAGTACTGGAGGAAGTCCCTGTCAATCAGAAAG
760      770      780      790      800      810      820

230
H Q A P Q D K
CACCAAGCTCCTCAAGACAAAGTGACACCCCATCCATCTATGGCAAAACATACGATGTTTGTGTCAGCAGCAA
835      845      855      865      875      885      895

```

TACACATAATGCCCTGGGTTTGACCTCCTATAATAAAGCAAAAAAAAAA
1285 1295 1305 1315 1325 1335

5/23

Figure 2a

Optimized score = 71
31.9% identity in 91 aa overlap


```

HLMSEB.aal MVWLPRVPCVAAVILLTLVLSPPVALVRDTRPRFLEYVTSECHFYNQTQHVRFLERFIYN
for alpha MFQNAHSGSQWLLPPLTILLFFAFADRQSA
HLMSEB.aal REENLRFSDVGEYRAVTELGRPDAENWNSQPEILEDARASVDITYCRHNYEISDKFLVRR
for alpha LPKAVVKLDPPWIIQVLKEDMVTLMCEGTH-NPGNSSTQWFHNGR-----SIRSQVQAS
HLMSEB.aal RVEPTVTVYPTKTQPLEHHNL-LVCSVSDFYPGNI EVRWFRNGKEEETGIVSTGLVRNGD
for alpha YTFKA-----TVNDSGE-YRCQMEQTRLSDPVDLGVISDWLLLTQTPQRVFLEGETITLRC
HLMSEB.aal WTFQTLVMLETVPQSGEVYTCQVEHPSLTDPVTVEWKAQSTSAQNKMLSGVGGFVLGLLF
for alpha HSWRNKLLNRISFFHNEKSVRYHHYKSNFSIPKANHSHSGDYCYCKGSLGSTQHQS KPVTI
HLMSEB.aal LGAGLFYFRNQKGQSGLQPTGLL
for alpha TVQDPATTSSISLVWYHTAFSLVMCLLFAVDTGLYFYVRRNLQTPREYWRKSLSIRKHQA
for alpha PQD

```

6/23

Figure 2b



7/23




Figure 3A

8/23

P388D1
S49.1
WEHI 3A
RAW264.7
J774
RBL-1
P388






Figure 3B

SUBSTITUTE SHEET

9/23

Figure 4a

 $\gamma_{2b}/\gamma_1 F_c R \beta_1$ (S49.1)

SUBSTITUTE SHEET

10/23

Figure 4b

GCTGGGGATTGTGATATAGAGAACCCAGATGGTGACTGAGGCCAAATGACTTCTGAGCTGGTTGCGGTCAGT
 85 95 105 115 125 135 145
 TTTCCTCTCTGTACGAGAGCTCCAGGTCCAGCTACGGCTCCAGCAGAACATGAGGGAGTTGTTTCTCAGTGTCT
 160 170 180 190 200 210 220
 AAAAAATTTTCTGTGATTTGAGCTGAATCCAGTTTATTCTGCCGGGAGGAGCCCTGTGCTGCAGCTGACTGGCT
 235 245 255 265 275 285 295
 CCAGAGCTGATGGGAAATCCTGCCGTTCTACTGATCCCATGGAGAGCAACTGGACTGTGCCATGCTTCTCAOGG
 310 320 330 340 350 360 370
 T L C H M L L W T A V L N L A A G T H D L P K A V
 ACTTTGTCGCATATGCTACTGTGGACAGCCGGTCTAAATCTTCTGCTGGACTCATCATCTTCCAAAGGCTCTG
 385 395 405 415 425 435 445
 V R L E P P W I Q V L K E D T V T L T \odot E G T H N
 10 20 30
 GTCNAACTCGAGCCCCCGTGGATCCAGGTGCTCAAGGAAGACACGGTGACACTGACATGCGAAGGGGACCCACAC
 460 470 480 490 500 510 520

11/23

Figure 4b, cont.

40 P G N S S T Q W F H N G R S I R S Q V Q A S Y T P
 50 CCTGGGAAC TCTTCTACCCAGTGGTTCACAAATGGGAGGTCCATCGGAGCCAGGTCCAGCCAGCTACACGTTT
 535 545 555 565 575 585 595
 60 K A T V N D S G E Y R Q M E Q T R L S D P V D L
 70 80
 610 620 630 640 650 660 670
 90 G V I S D W L L Q T P O L V F L E G E T I T L R
 100 GGAGTGATTCTGACTGGCTGCTCCAGACCCCTCAGCTGGTGTCTGGAGGGGAAACCATCAGCTAAGG
 685 695 705 715 725 735 745
 110 C H S W R N K L L N R I S P P H N E K S V R Y H H
 120 130
 760 770 780 790 800 810 820
 140 Y S S N F S I P K A N H S H S G D Y Y C K G S L G
 150 160 170 180
 835 845 855 865 875 885 895
 160 R T L H Q S K P V T I T V Q G P K S S R S L P V L
 170 180
 910 920 930 940 950 960 970
 980 990
 AGGACACTGCACCAGTCCAGCCCTGTCACCATCAGTGTCCAGGGCCAGTCCAGCCAGGTCTTTACCACTATG

12/23

Figure 4b, cont.

190 T T V A A A V T C Y A V A A A Y V T I L V S L V Y L R
 985 ACAATTGTCGCTGCTCAGTCGGATTGCTGTCAGCCCATGTTATTATCTAGTATCTTGGTCTATCTCAAG
 1005 1015 1025 1035 1045
 210
 220
 230
 240
 250
 260
 270
 280
 290
 300
 310
 320
 330
 340
 350
 360
 370
 380
 390
 400
 410
 420
 430
 440
 450
 460
 470
 480
 490
 500
 510
 520
 530
 540
 550
 560
 570
 580
 590
 600
 610
 620
 630
 640
 650
 660
 670
 680
 690
 700
 710
 720
 730
 740
 750
 760
 770
 780
 790
 800
 810
 820
 830
 840
 850
 860
 870
 880
 890
 900
 910
 920
 930
 940
 950
 960
 970
 980
 990
 1000
 1010
 1020
 1030
 1040
 1050
 1060
 1070
 1080
 1090
 1100
 1110
 1120
 1130
 1140
 1150
 1160
 1170
 1180
 1190
 1200
 1210
 1220
 1230
 1240
 1250
 1260
 1270
 1280
 1290
 1300
 1310
 1320
 1330
 1340
 1350
 1360
 1370
 1380
 1390
 1400
 1410
 1420
 1430
 1440
 1450
 1460
 1470
 1480
 1490
 1500
 1510
 1520
 1530
 1540
 1550
 1560
 1570
 1580
 1590
 1600
 1610
 1620
 1630
 1640
 1650
 1660
 1670
 1680
 1690
 1700
 1710
 1720
 1730
 1740
 1750
 1760
 1770
 1780
 1790
 1800
 1810
 1820
 1830
 1840
 1850
 1860
 1870
 1880
 1890
 1900
 1910
 1920
 1930
 1940
 1950
 1960
 1970
 1980
 1990
 2000
 2010
 2020
 2030
 2040
 2050
 2060
 2070
 2080
 2090
 2100
 2110
 2120
 2130
 2140
 2150
 2160
 2170
 2180
 2190
 2200
 2210
 2220
 2230
 2240
 2250
 2260
 2270
 2280
 2290
 2300
 2310
 2320
 2330
 2340
 2350
 2360
 2370
 2380
 2390
 2400
 2410
 2420
 2430
 2440
 2450
 2460
 2470
 2480
 2490
 2500
 2510
 2520
 2530
 2540
 2550
 2560
 2570
 2580
 2590
 2600
 2610
 2620
 2630
 2640
 2650
 2660
 2670
 2680
 2690
 2700
 2710
 2720
 2730
 2740
 2750
 2760
 2770
 2780
 2790
 2800
 2810
 2820
 2830
 2840
 2850
 2860
 2870
 2880
 2890
 2900
 2910
 2920
 2930
 2940
 2950
 2960
 2970
 2980
 2990
 3000
 3010
 3020
 3030
 3040
 3050
 3060
 3070
 3080
 3090
 3100
 3110
 3120
 3130
 3140
 3150
 3160
 3170
 3180
 3190
 3200
 3210
 3220
 3230
 3240
 3250
 3260
 3270
 3280
 3290
 3300
 3310
 3320
 3330
 3340
 3350
 3360
 3370
 3380
 3390
 3400
 3410
 3420
 3430
 3440
 3450
 3460
 3470
 3480
 3490
 3500
 3510
 3520
 3530
 3540
 3550
 3560
 3570
 3580
 3590
 3600
 3610
 3620
 3630
 3640
 3650
 3660
 3670
 3680
 3690
 3700
 3710
 3720
 3730
 3740
 3750
 3760
 3770
 3780
 3790
 3800
 3810
 3820
 3830
 3840
 3850
 3860
 3870
 3880
 3890
 3900
 3910
 3920
 3930
 3940
 3950
 3960
 3970
 3980
 3990
 4000
 4010
 4020
 4030
 4040
 4050
 4060
 4070
 4080
 4090
 4100
 4110
 4120
 4130
 4140
 4150
 4160
 4170
 4180
 4190
 4200
 4210
 4220
 4230
 4240
 4250
 4260
 4270
 4280
 4290
 4300
 4310
 4320
 4330
 4340
 4350
 4360
 4370
 4380
 4390
 4400
 4410
 4420
 4430
 4440
 4450
 4460
 4470
 4480
 4490
 4500
 4510
 4520
 4530
 4540
 4550
 4560
 4570
 4580
 4590
 4600
 4610
 4620
 4630
 4640
 4650
 4660
 4670
 4680
 4690
 4700
 4710
 4720
 4730
 4740
 4750
 4760
 4770
 4780
 4790
 4800
 4810
 4820
 4830
 4840
 4850
 4860
 4870
 4880
 4890
 4900
 4910
 4920
 4930
 4940
 4950
 4960
 4970
 4980
 4990
 5000
 5010
 5020
 5030
 5040
 5050
 5060
 5070
 5080
 5090
 5100
 5110
 5120
 5130
 5140
 5150
 5160
 5170
 5180
 5190
 5200
 5210
 5220
 5230
 5240
 5250
 5260
 5270
 5280
 5290
 5300
 5310
 5320
 5330
 5340
 5350
 5360
 5370
 5380
 5390
 5400
 5410
 5420
 5430
 5440
 5450
 5460
 5470
 5480
 5490
 5500
 5510
 5520
 5530
 5540
 5550
 5560
 5570
 5580
 5590
 5600
 5610
 5620
 5630
 5640
 5650
 5660
 5670
 5680
 5690
 5700
 5710
 5720
 5730
 5740
 5750
 5760
 5770
 5780
 5790
 5800
 5810
 5820
 5830
 5840
 5850
 5860
 5870
 5880
 5890
 5900
 5910
 5920
 5930
 5940
 5950
 5960
 5970
 5980
 5990
 6000
 6010
 6020
 6030
 6040
 6050
 6060
 6070
 6080
 6090
 6100
 6110
 6120
 6130
 6140
 6150
 6160
 6170
 6180
 6190
 6200
 6210
 6220
 6230
 6240
 6250
 6260
 6270
 6280
 6290
 6300
 6310
 6320
 6330
 6340
 6350
 6360
 6370
 6380
 6390
 6400
 6410
 6420
 6430
 6440
 6450
 6460
 6470
 6480
 6490
 6500
 6510
 6520
 6530
 6540
 6550
 6560
 6570
 6580
 6590
 6600
 6610
 6620
 6630
 6640
 6650
 6660
 6670
 6680
 6690
 6700
 6710
 6720
 6730
 6740
 6750
 6760
 6770
 6780
 6790
 6800
 6810
 6820
 6830
 6840
 6850
 6860
 6870
 6880
 6890
 6900
 6910
 6920
 6930
 6940
 6950
 6960
 6970
 6980
 6990
 7000
 7010
 7020
 7030
 7040
 7050
 7060
 7070
 7080
 7090
 7100
 7110
 7120
 7130
 7140
 7150
 7160
 7170
 7180
 7190
 7200
 7210
 7220
 7230
 7240
 7250
 7260
 7270
 7280
 7290
 7300
 7310
 7320
 7330
 7340
 7350
 7360
 7370
 7380
 7390
 7400
 7410
 7420
 7430
 7440
 7450
 7460
 7470
 7480
 7490
 7500
 7510
 7520
 7530
 7540
 7550
 7560
 7570
 7580
 7590
 7600
 7610
 7620
 7630
 7640
 7650
 7660
 7670
 7680
 7690
 7700
 7710
 7720
 7730
 7740
 7750
 7760
 7770
 7780
 7790
 7800
 7810
 7820
 7830
 7840
 7850
 7860
 7870
 7880
 7890
 7900
 7910
 7920
 7930
 7940
 7950
 7960
 7970
 7980
 7990
 8000
 8010
 8020
 8030
 8040
 8050
 8060
 8070
 8080
 8090
 8100
 8110
 8120
 8130
 8140
 8150
 8160
 8170
 8180
 8190
 8200
 8210
 8220
 8230
 8240
 8250
 8260
 8270
 8280
 8290
 8300
 8310
 8320
 8330
 8340
 8350
 8360
 8370
 8380
 8390
 8400
 8410
 8420
 8430
 8440
 8450
 8460
 8470
 8480
 8490
 8500
 8510
 8520
 8530
 8540
 8550
 8560
 8570
 8580
 8590
 8600
 8610
 8620
 8630
 8640
 8650
 8660
 8670
 8680
 8690
 8700
 8710
 8720
 8730
 8740
 8750
 8760
 8770
 8780
 8790
 8800
 8810
 8820
 8830
 8840
 8850
 8860
 8870
 8880
 8890
 8900
 8910
 8920
 8930
 8940
 8950
 8960
 8970
 8980
 8990
 9000
 9010
 9020
 9030
 9040
 9050
 9060
 9070
 9080
 9090
 9100
 9110
 9120
 9130
 9140
 9150
 9160
 9170
 9180
 9190
 9200
 9210
 9220
 9230
 9240
 9250
 9260
 9270
 9280
 9290
 9300
 9310
 9320
 9330
 9340
 9350
 9360
 9370
 9380
 9390
 9400
 9410
 9420
 9430
 9440
 9450
 9460
 9470
 9480
 9490
 9500
 9510
 9520
 9530
 9540
 9550
 9560
 9570
 9580
 9590
 9600
 9610
 9620
 9630
 9640
 9650
 9660
 9670
 9680
 9690
 9700
 9710
 9720
 9730
 9740
 9750
 9760
 9770
 9780
 9790
 9800
 9810
 9820
 9830
 9840
 9850
 9860
 9870
 9880
 9890
 9900
 9910
 9920
 9930
 9940
 9950
 9960
 9970
 9980
 9990
 10000
 10010
 10020
 10030
 10040
 10050
 10060
 10070
 10080
 10090
 10100
 10110
 10120
 10130
 10140
 10150
 10160
 10170
 10180
 10190
 10200
 10210
 10220
 10230
 10240
 10250
 10260
 10270
 10280
 10290
 10300
 10310
 10320
 10330
 10340
 10350
 10360
 10370
 10380
 10390
 10400
 10410
 10420
 10430
 10440
 10450
 10460
 10470
 10480
 10490
 10500
 10510
 10520
 10530
 10540
 10550
 10560
 10570
 10580
 10590
 10600
 10610
 10620
 10630
 10640
 10650
 10660
 10670
 10680
 10690
 10700
 10710
 10720
 10730
 10740
 10750
 10760
 10770
 10780
 10790
 10800
 10810
 10820
 10830
 10840
 10850
 10860
 10870
 10880
 10890
 10900
 10910
 10920
 10930
 10940
 10950
 10960
 10970
 10980
 10990
 11000
 11010
 11020
 11030
 11040
 11050
 11060
 11070
 11080
 11090
 11100
 11110
 11120
 11130
 11140
 11150
 11160
 11170
 11180
 11190
 11200
 11210
 11220
 11230
 11240
 11250
 11260
 11270
 11280
 11290
 11300
 11310
 11320
 11330
 11340
 11350
 11360
 11370
 11380
 11390
 11400
 11410
 11420
 11430
 11440
 11450
 11460
 11470
 11480
 11490
 11500
 11510
 11520
 11530
 11540
 11550
 11560
 11570
 11580
 11590
 11600
 11610
 11620
 11630
 11640
 11650
 11660
 11670
 11680
 11690
 11700
 11710
 11720
 11730
 11740
 11750
 11760
 11770
 11780
 11790
 11800
 11810
 11820
 11830
 11840
 11850
 11860
 11870
 11880
 11890
 11900
 11910
 11920
 11930
 11940
 11950
 11960
 11970
 11980
 11990
 12000
 12010
 12020
 12030
 12040
 12050
 12060
 12070
 12080
 12090
 12100
 12110
 12120
 12130
 12140
 12150
 12160
 12170
 12180
 12190
 12200
 12210
 12220
 12230
 12240
 12250
 12260
 12270
 12280
 12290
 12300
 12310
 12320
 12330
 12340
 12350
 12360
 12370
 12380
 12390
 12400
 12410
 12420
 12430
 12440
 12450
 12460
 12470
 12480
 12490
 12500
 12510
 12520
 12530
 12540
 12550
 12560
 12570
 12580
 12590
 12600
 12610
 12620
 12630
 12640
 12650
 12660
 12670
 12680
 12690
 12700
 12710
 12720
 12730
 12740
 12750
 12760
 12770
 12780
 12790
 12800
 12810
 12820
 12830
 12840
 12850
 12860
 12870
 12880
 12890
 12900
 12910
 12920
 12930
 12940
 12950
 12960
 12970
 12980
 12990
 13000
 13010
 13020
 13030
 13040
 13050
 13060
 13070
 13080
 13090
 13100
 13110
 13120
 13130
 13140
 13150
 13160
 13170
 13180
 13190
 13200
 13210
 13220
 13230
 13240
 13250
 13260
 13270
 13280
 13290
 13300
 13310
 13320
 13330
 13340
 13350

13/23

Figure 5

```

for beta 1 MESNWTVHVFSRTLCHMLLWTAVLNLAAGTHDLPKAVVKLEPPWIQVLKEDTVTLTCEGT
for alpha  MFCNAHSGSQWLLPPLTILLFAFADRQSAALPKAVVKLDPPWIQVLKEDHVTLMCEGT
               ::::::::::::::::::::::::::::::::::::::::::::::::::::::
for beta 1 HNPGRNSTQWFHNGRSIRSQVQASYTFKATVNDSGEYRCQMEQTRLSDPVDLGVISDWLL
               ::::::::::::::::::::::::::::::::::::::::::::::::::::::
for alpha  HNPGRNSTQWFHNGRSIRSQVQASYTFKATVNDSGEYRCQMEQTRLSDPVDLGVISDWLL
               ::::::::::::::::::::::::::::::::::::::::::::::::::::::
for beta 1 LQTPQLVFLEGETITLRRCHSWRNKLLNRIISFFHNEKSVRYHHYSSNFSIPKANHSHSGDY
               ::::::::::::::::::::::::::::::::::::::::::::::::::::::
for alpha  LQTPQRVFLEGETITLRRCHSWRNKLLNRIISFFHNEKSVRYHHYKSNFSIPKANHSHSGDY
               ::::::::::::::::::::::::::::::::::::::::::::::::::::::
for beta 1 YCKGSLGRTLHQSKPVTITVQGPCKSSRSLPVLTIVAAVTGI AVAAI VI ILVSLVYLKKKQ
               ::::::::::::::::::::::::::::::::::::::::::::::::::::::
for alpha  YCKGSLGSTQHQS KPV TITVQDPATTSSISLVWYHTAFSLVMCLLFAVDGTGLYFYVRRNL
               ::::::::::::::::::::::::::::::::::::::::::::::::::::::
for beta 1 VPALPGNPDHREMGETLPEEVGEYRQPSGLSACQPRAPSGLEPTSSSPYNPPDLEEAAT
for alpha  QTPREYWRKSL SIRKHKQAPQD
               ::::::::::::::::::::::::::::::::::::::::::::::::::::::
for beta 1 EAENTITYSLKKHPEALDEETEHDYQNH

```

SUBSTITUTE SHEET

14/23





Figure 6A
SUBSTITUTE SHEET

15/23





Figure 6B

SUBSTITUTE SHEET

P388D1
S49.1
WEHI 3A
RAW264.7
J774
P388
J774
RBL-1
CL.7
L-Cell
L5178Y

- 28

- 18




Figure 7A

SUBSTITUTE SHEET

P388D1
S49.1
WEHI 3A
RAW264.7
J774
RBL-1
P388

-28

-18




Figure 7B

SUBSTITUTE SHEET

Figure 8a


 $\gamma_{2b}/\gamma_1 F_c R \beta_2$ 

Figure 8b

M E S N W T V
 CTTCAGCTGACTGCTCCAGAGCTGATGGGAATCCTGCGTTCCTACTGATCCCATGGAGAGCAACTGGACTG
 10 20 30 40 50 60 70
 -20
 H V F S R T L C H M L L W T A V L N L A A G T H D
 TCCATGTGTTCTCAOGGACTTTGTGCCATATGCTACTGTGGACAGCGTGCTAAATCTTGCTGCTGGGACTCATG
 85 95 105 115 125 135 145
 -10
 L P K A V V K L E P P W I Q V L K E D T V T L T C
 ATCTTCCAAAGGCTGTGGTCAAACTCGAGCCCGTGGATCCAGGTGCTCAAGGAAGACACGGTGACACTGACAT
 160 170 180 190 200 210 220
 30
 E G T H N P G N S S T Q W F H N G R S I R S Q V Q
 GCGAAGGACCCACAAACCTGCGAACTCTTCTACCCAGTGTTCACAAATGGAGGTCCATCCGGAGCCAGGTCC
 235 245 255 265 275 285 295
 60
 A S Y T F K A T V N D S G E Y R Q M E Q T R L S
 AAGCCAGCTACACGTTTAAGGCCACAGTCAAATGACAGTGGAGAAATATCGGTGTCAAATGGAGCAGACCCGCTCA
 310 320 330 340 350 360 370

20/23

Figure 8b, cont.

80 P V D L G V I S D W L L L Q T P Q L V F L E G E
D P V D L G V I S D W L L L Q T P Q L V F L E G E
GGACCCCTGTAGATCTGGGAGTGATTTCTGACTGGCTGCTCCAGACCCCTCAGCTGGTGTCTTCTGGAAGGGG
385 395 405 415 425 435 445

110 T I T L R C H S W R N K L L N R I S P P H N E K S
AAACCATCAGCGCTAAGGTGCCATAGCTGGAGGAACAACTACTGAACAGGATCTCGTTCTTCCATATGAAAAAT
460 470 480 490 500 510 520

130 V R Y H H Y S S N F S I P K A N H S H S G D Y Y C
CCGTGAGGTATCATCACTACAGTAGTAATTTCTCTATCCCAAGCCACACAGTCACAGTGGGGACTACTACT
535 545 555 565 575 585 595

160 K G S L G R T L H Q S K P V T I T V Q G P K S S R
GCAAGGAAGTCTAGGAAGGACACTGCCACCAGTCCAGCCCTGTCCACCATCACTGTCCAGGGCCCAAGTCCAGCA
610 620 630 640 650 660 670

180 S L P V L T I V A A V T G I A V A A I V I L V S
GGTCTTTACCAAGTATGACAATTTGGCTGCTGTCACCTGGGATGCTGTGCGAGCCATTGTTATTCCTAGTAT
685 695 705 715 725 735 745

SUBSTITUTE SHEET

Figure 8b, cont.

```

      210      220
L V Y L K K Q V P D N P P D L E E A A K T E A E
CCTGGTCTATCTCAAGAAAGCAGGGTTCCAGACAATCCTCTGATCTGGAGAGCTGCCAAACTGAGGCTG
760      770      780      790      800      810      820

      230      240      250
N T I T Y S L L K H P E A L D E E T E H D Y Q N H
AGNATACGATCACCTACTCACTTCTCAAGCATCCCGAAGCCCTGGATGAAGAAACAGAGCATGATTACCAGAACC
835      845      855      865      875      885      895

      254
I
ACATTAGTCTCCCTTGGCA TTGGGAAAGCAAGCCAGAAAGGCCAGGATCTAGTGTCTCTGGTCCAGGGATG
910      920      930      940      950      960      970

      CTGTAGATATTNAGAAACATCCAGAGTCACCTTCTGTGAGTCCTGAAACCACAGACACTAGAGATTGGTTCC
985      995      1005      1015      1025      1035      1045

      CAATGGTTGACTGTACTAATGACTCCCATTAACCTTACAGCTTCCCAACTCAAGAGCTCTTCTGCTATCGATCCACAC
1060      1070      1080      1090      1100      1110      1120

      TGCCACTAAATTAATCAACTTACTGCGGTTANGAGA
1135      1145      1155

```

SUBSTITUTE SHEET





Figure 9

SUBSTITUTE SHEET

Figure 10



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US87/02845

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ¹		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC(4): C12P 21/00; C12P 21/02; C12P 19/34; See Attachment US CL : 435/68; 435/70; 435/91; 435/172.3; See Attachment		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	435/68, 70, 91, 172.3, 240.2, 240.241, 320 536/27 935/12, 32, 34, 78	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁵		
CHEMICAL ABSTRACTS, DATA BASE (CAS) 1967-1988; BIOLOGICAL ABSTRACTS DATA BASE (BIOSIS) 1967-1988 KEYWORDS: IMMUNOGLOBULIN, Fe, HEAVY CHAIN, RECEPTOR, RECOMBINANT, PLASMID		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category [*]	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X, P	SCIENCE, (Washington, D.C.) Volume 234, issued 7 November 1986 (RAVETCH ET AL) "Structural Heterogeneity and Functional Domains of Murine Immunoglobulin G Fc Receptors". See pages 718-725..	1-25
X Y	US, A, 4,617,266 (FAHNESTOCK) 14 October 1986. See columns 5-8.	1-6, 10-14, 19 7-9, 15-18, 20-25
X Y	JOURNAL OF BACTERIOLOGY (Washington, D.C.), Volume 167, issued 2 September 1986 (FAHNESTOCK ET AL) "Gene for an Immunoglobulin-Binding Protein from a Group G <u>Streptococcus</u> ". See pages 870-880.	1-6, 10-14, 19 7-9, 15-18, 20-25
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>[*] Special categories of cited documents: ¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ¹	Date of Mailing of this International Search Report ¹	
29 January 1988	10 FEB 1988	
International Searching Authority ¹	Signature of Authorized Officer ¹⁰	
ISA/US	Thomas D. Mays	

PCT/US87/02845

Attachment To Form PCT/ISA/210, Part I.

IPC(4): C12N 15/00; C12N 5/00; C07H 15/12; C07H 13/00

US CL : 435/240.2, 240.241; 536/27; 530/388

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, 1 st with indication, where appropriate, of the relevant passages 1 st	Relevant to Claim No 1 st
Y	<u>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (USA)</u> (Washington, D.C.), Volume 83, issued September 1986 (HIBBS ET AL), "The Murine Fc Receptor For Immunoglobulin: Purification, Partial Amino Acid Sequence, and Isolation of cDNA Clones". See pages 6980-6984.	1-25
$\frac{X}{Y}$	<u>THE EMBO JOURNAL</u> (Oxford, UK), Volume 5, issued July 1986 (GUSS ET AL) "Structure of the IgG-Binding Regions of Streptococcal Protein G". See pages 1567-1575.	1-6, 10-14, 19 7-9, 15-18, 20-25
Y	<u>NATURE</u> (London) Volume 308, issued 1 March 1984 (MOSTOV ET AL) "The Receptor for Transepithelial Transport of IgA and IgM Contains Multiple Immunoglobulin-like Domains". See pages 37-43.	1-25